fremanezumab has completed phase iii trials and is under review by the fda to prevent migraine and
.
.
.
.
.
�this negligence must not be allowed to continue,� budkie�s letter states. �the university of california, berkeley, has clearly failed to follow federal regulations and guidelines.�
.
.
.
.